Effects of rosiglitazone on the cardiovascular profile in postmenopausal women without diabetes mellitus: Interplay of thiazolidinediones and hormone therapy

Menopause

Volumn 19, Issue 7, 2012, Pages 812-819

  Chen, I Chih ^a,b   Lee, Wen Huang ^c   Chao, Ting Hsing ^a,c   Li, Yi Heng ^a   Tsai, Wei Chuan ^a   Pan, Hsien An ^a   Tseng, Shih Ya ^d   Chen, Ju Yi ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b TAINAN MUNICIPAL HOSPITAL   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

Hormone therapy; Insulin resistance; Menopause; Peroxisome proliferator activated receptor; Rosiglitazone

Indexed keywords

CONJUGATED ESTROGEN; GELATINASE B; GESTAGEN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; SALBUTAMOL; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR PROFILE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HORMONAL THERAPY; HUMAN; INSULIN BLOOD LEVEL; LEUKOCYTE COUNT; NORMAL HUMAN; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; WAIST CIRCUMFERENCE; WEIGHT GAIN;

AGED; BODY SIZE; CARDIOVASCULAR SYSTEM; CHOLESTEROL, LDL; DIABETES MELLITUS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGLYCEMIC AGENTS; LEUKOCYTE COUNT; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATORS; POSTMENOPAUSE; PROSPECTIVE STUDIES; RISK FACTORS; SERINE PROTEINASE INHIBITORS; THIAZOLIDINEDIONES;

EID: 84863528804     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e3182400ec0     Document Type: Article

References (67)

1. Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 2000;43:278-284. (Pubitemid 30163470)
2. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann InternMed 2001;134: 61-71. (Pubitemid 32037344)
3. Duan SZ, Usher MG, Mortensen RM. Peroxisome proliferator-activated receptor-F-mediated effects in the vasculature. Circ Res 2008;102:283-294. (Pubitemid 351271648)
4. Tseng CH, Huang TS. Pioglitazone with sulfonylurea: glycemic and lipid effects in Taiwanese type 2 diabetic patients. Diabetes Res Clin Pract 2005;70:193-194.
5. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-684. (Pubitemid 34851926)
6. Nordt TK, Peter K, Bode C, Sobel BE. Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells. J Clin Endocrinol Metab 2000;85:1563-1568. (Pubitemid 32289501)
7. Marx N, Froehlich J, Siam L, et al. Antidiabetic PPARF-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003;23:283-288. (Pubitemid 36231941)
8. Randriamboavonjy V, Pistrosch F, Bölck B, et al. Platelet sarcoplasmic endoplasmic reticulum Ca2+ATPase and mu-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone. Circulation 2008;117:52-60. (Pubitemid 350291181)
9. Yu J, Jin N, Wang G, Zhang F, Mao J, Wang X. Peroxisome proliferatoractivated receptor F agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease. Metabolism 2007;56: 1396-1401. (Pubitemid 47404603)
10. Rosmarakis ES, Falagas ME. Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials. Am Heart J 2007;154:144-150. (Pubitemid 46920490)
11. Sorrentino SA, Bahlmann FH, Besler C, et al. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-F agonist rosiglitazone. Circulation 2007;116: 163-173. (Pubitemid 47057522)
12. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003;26:172-178. (Pubitemid 36929012)
13. Wang TD, Chen WJ, Lin JW, Chen MF, Lee YT. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol 2004;93:362-365.
14. Esposito K, Ciotola M, Carleo D, et al. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care 2006;29:1071-1076. (Pubitemid 44115246)
15. Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease. Ann Intern Med 1978;89:157-161.
16. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennenkens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987;316:1105-1110. (Pubitemid 17052498)
17. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. N Engl J Med 1989;321:641-646. (Pubitemid 19221308)
18. Kuh D, Langenberg C, Hardy R, et al. Cardiovascular risk at age 53 years in relation to the menopause transition and use of hormone replacement therapy: a prospective British birth cohort study. BJOG 2005;112: 476-485. (Pubitemid 40516564)
19. Matthews KA, Crawford SL, Chae CU, et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol 2009;54: 2366-2373.
20. Curry TE, Osteen KG. Cyclic changes in the matrix metalloproteinase system in the ovary and uterus. Biol Reprod 2001;64:1285-1296. (Pubitemid 32373046)
21. Chang CJ, Wu CH, Yao WJ, Tang YC, Wu JS, Lu FH. Relationships of age, menopause and central obesity on cardiovascular disease risk factors in Chinese women. Int J Obes Relat Metab Disord 2000;24:1699-1704.
22. Donato GB, Fuchs SC, Oppermann K, Bastos C, Spritzer PM. Association between menopause status and central adiposity measured at different cutoffs of waist circumference and waist-to-hip ratio. Menopause 2006;13:280-285.
23. Wu SI, Chou P, Tsai ST. The impact of years since menopause on the development of impaired glucose tolerance. J Clin Epidemiol 2001;54: 117-120. (Pubitemid 32112369)
24. Gayoso-Diz R, Otero-Gonzalez A, Rodriquez-Alvarez MX, et al. Insulin resistance index (HOMA-IR) levels in a general adult population: Curves percentile by gender and age. The EPIRCE study. Diabetes Res Clin Pract 2011;94:146-155.
25. Su TC, Bai CH, Chang HY, et al. Evidence for improved control of hypertension in Taiwan: 1993-2002. J Hypertens 2008;26:600-606.
26. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-1811. (Pubitemid 29266405)
27. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:217-221. (Pubitemid 27057346)
28. Sarrel PM. How progestins compromise the cardioprotective effects of estrogens. Menopause 1995;2:187-190.
29. Cushman M, Meilahn EN, Psaty BM, Kuller LH, Dobs AS, Tracy RP. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol 1999;19:893-899. (Pubitemid 29177335)
30. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 2002;288:980-987. (Pubitemid 34920463)
31. Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996;348:983-987. (Pubitemid 26340753)
32. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997;350:1047-1059.
33. Hu P, Greendale GA, Palla SL, et al. The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: the postmenopausal estrogen progestin intervention (PEPI) trial. Atherosclerosis 2006;185: 347-352.
34. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. JAMA 2002;288:49-57.
35. Alexander KP, Newby LK, Hellkamp AS, et al. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. J Am Coll Cardiol 2001;38:1-7. (Pubitemid 32613820)
36. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-333.
37. Barchiesi F, Lucchinette E, Zaugg M, et al. Candidate genes and mechanisms for 2-methoxyestradiol-mediated vasoprotection. Hypertension 2010;56:964-972.
38. Willy PJ, Murray IR, Qian J, et al. Regulation of PPARF coactivator 1> (PGC-1>) signaling by an estrogen-related receptor > (ERR>) ligand. Proc Natl Acad Sci USA 2004;101:8912-8917. (Pubitemid 38781585)
39. Zhu LL, Liu Y, Cui AF, et al. PGC-1> coactivates estrogen-related receptor-> to induce the expression of glucokinase. Am J Physiol Endocrinol Metab 2010;298:E1210-E1218.
40. Honisett SY, Stojanovska L, Sudhir K, Kingwell BA, Dawood T, Komesaroff PA. Hormone therapy impairs endothelial function in postmenopausal women with type 2 diabetes mellitus treated with rosiglitazone. J Clin Endocrinol Metab 2004;89:4615-4619. (Pubitemid 39244478)
41. Fayard JM, Chanal S, Felouati B, et al. Regulation of quail oviduct phospholipase A2 activity by estradiol. Eur J Endocrinol 1994;131: 205-212. (Pubitemid 24265356)
42. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor F and promotes adipocyte differentiation. Cell 1995;83:813-819. (Pubitemid 3006325)
43. Stafylas PC, Sarafidis PA, Lasaridis AN. The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality. Int J Cardiol 2009;131:298-304.
44. Wang N, Yin R, Liu Y, Mao G, Xi F. Role of peroxisome proliferatoractivated receptor-F in atherosclerosis: an update. Circ J 2011;75:528-535.
45. Chao TH, Tsai LM, Tsai WC, Li YH, Lin LJ, Chen JH. Effect of atrial fibrillation on pulmonary venous flow patterns assessed by Doppler transesophageal echocardiography. Chest 2000;117:1546-1550.
46. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and A-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419. (Pubitemid 15018832)
47. Hijmering ML, Stroes ES, Pasterkamp G, Sierevogel M, Banga JD, Rabelink TJ. Variability of flow mediated dilation: consequences for clinical application. Atherosclerosis 2001;157:369-373. (Pubitemid 32710015)
48. De Roos NM, Bots ML, Schouten EG, Katan MB. Within-subject variability of flow-mediated vasodilation of the brachial artery in healthy men and women: implications for experimental studies. Ultrasound Med Biol 2003;29:401-406. (Pubitemid 36434328)
49. Malik J, Wichterle D, Haas T, Melenovsky V, Simek J, Stulc T. Repeatability of noninvasive surrogates of endothelial function. Am J Cardiol 2004;94:693-696. (Pubitemid 39165862)
50. McEniery CM, Wallace S, Mackenzie IS, et al. Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans. Hypertension 2006;48:602-608. (Pubitemid 44843862)
51. Chen IC, Chao TH, Tsai WC, Li YH. Rosiglitazone reduces plasma levels of inflammatory and haemostatic biomarkers and improves global endothelial function in habitual heavy smokers without diabetes mellitus and metabolic syndrome. J Formos Med Assoc 2010;109:113-119.
52. Chowienczyk PJ, Kelly RP, MacCallum H, et al. Photoplethysmographic assessment of pulse wave reflection. J Am Coll Cardiol 1999;34: 2007-2014.
53. Hayward CS, Kraidly M, Webb CM, Collins P. Assessment of endothelial function using peripheral waveform analysis. A clinical application. J Am Coll Cardiol 2002;40:521-528. (Pubitemid 34833170)
54. Wilkinson IB, Hall IR, MacCallum H, et al. Pulse wave analysis. Clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function. Arterioscler Thromb Vasc Biol 2002;22:147-152. (Pubitemid 34076246)
55. Gopaul NK, Manraj MD, Hébé A, et al. Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism. Diabetologia 2001;44:706-712. (Pubitemid 32846025)
56. Hetzel J, Balletshofer B, Rittig K, et al. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol 2005;25:1804-1809. (Pubitemid 41243446)
57. Honisett SY, Stojanovska L, Sudhir K, Kingwell BA, Dawood T, Komesaroff PA. Rosiglitazone lowers blood pressure and increases arterial compliance in postmenopausal women with type 2 diabetes. Diabetes Care 2003;26:3194-3195. (Pubitemid 37339529)
58. Derosa G, Cicero AF, Gaddi AV, et al. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. Clin Ther 2005;27: 1383-1391. (Pubitemid 41598369)
59. Serra D, He YL, Bullock J, et al. Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with type 2 diabetes. Int J Clin Pharmacol Ther 2008;46:349-364. (Pubitemid 352005928)
60. Pradhan AD, LaCroix AZ, Langer RD, et al. Tissue plasminogen activator antigen and D-dimer as markers for atherothrombotic risk among healthy postmenopausal women. Circulation 2004;110:292-300. (Pubitemid 38955498)
61. Reiner AP, Aragaki AK, Gray SL, et al. Inflammation and thrombosis biomarkers and incident frailty in postmenopausal women. Am J Med 2009;122:947-954.
62. Farrow B, O'Conner KL, Hashimoto K, Iwamura T, Evers BM. Selective activation of PPARF inhibits pancreatic cancer invasion and decreases expression of tissue plasminogen activator. Surgery 2003;134:206-212. (Pubitemid 37070340)
63. Shahar E, Folsom AR, Salomaa W, et al. Relation of hormonereplacement therapy to measures of plasma fibrinolytic activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 1996;93:1970-1975. (Pubitemid 126424496)
64. Zanger D, Yang BK, Ardans J, et al. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J Am Coll Cardiol 2000;36:1797-1802.
65. Schernthaner G, Barnett AH, Betteridge DJ, et al. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia 2010;53: 1258-1269.
66. Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008;168: 2070-2080.
67. Monami M, Marchionni N, Mannucci E. Winners and losers at the rosiglitazone gamble. A meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone. Diabetes Res Clin Pract 2008;82:48-57.